Although there is variability in the diagnostic accuracy of the PSA test, the specificity of PSA testing for detecting clinically important prostate cancer may be improved when followed by other assessment methods, such as a risk calculator [80] or mpMRI [81]. This evidence concerns the gene KLK3 and prostate cancer.